cyclopentylmethyl chloroformate | 38240-04-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: cyclopentylmethyl chloroformate
• 英文别名: cyclopentylmethyl carbonochloridate
• CAS: 38240-04-9
• 化学式: C₇H₁₁ClO₂
• 分子量: 162.616
• InChiKey: DDPRIBJJDYHQDB-UHFFFAOYSA-N

物化性质

• 沸点：
  202.1±9.0 °C(Predicted)
• 密度：
  1.151±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  cyclopentylmethyl chloroformate 在 4-二甲氨基吡啶 、 sodium hydroxide 、 1-羟基苯并三唑 、 戴斯-马丁氧化剂 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 生成 3-((S)-2-Cyclopentylmethoxycarbonylamino-3-methyl-butyrylamino)-5-fluoro-4-oxo-pentanoic acid
  参考文献：
  名称：

  Dipeptidyl aspartyl fluoromethylketones as potent caspase inhibitors: SAR of the N-protecting group

  摘要：

  This article describes the synthesis and biological evaluation of a group of N-protected Val-Asp-fmk as caspase inhibitors. The protecting group was found to contribute to caspase-3 inhibiting activity, and compounds with a large group such as Cbz are more active than compounds with a small group such as Ac. Compounds with more hydrophobic protecting groups were found to be more active in cell apoptosis protection assays, probably due to increased cell permeability. MX1122,2,4-di-Cl-Cbz-Val-Aspfmk, is identified as a potent broad-spectrum caspase inhibitor and is selective for caspases versus other proteases, with good activity in the cell apoptosis protection assays as well as good efficacy in the mouse liver apoptosis model. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.08.027
• 作为产物：
  描述：

  光气 、 环戊基甲醇 生成 cyclopentylmethyl chloroformate
  参考文献：
  名称：

  Beta lactam compounds and their use as inhibitors of tryptase

  摘要：

  这些化合物的结构式已被披露。这些化合物抑制色胺酸蛋白酶以及其他酶系统，或者是选择性色胺酸蛋白酶抑制剂，并且在特别是治疗慢性哮喘方面作为抗炎药物是有用的。

  公开号：

  US06335324B1

文献信息

• Phosphonoformic acid esters and pharmaceutical compositions containing
  申请人：Astra Lakemedel Aktiebolag

  公开号：US04386081A1

  公开（公告）日：1983-05-31

  A pharmaceutical preparation containing as active ingredient a compound of the formula ##STR1## wherein R.sub.1 and R.sub.2 are the same or different, and each is selected from the group consisting of hydrogen, alkyl groups containing 1-6 carbon atoms; cycloalkyl groups containing 3-6 carbon atoms; cycloalkyl-alkyl groups containing 4-6 carbon atoms; 1-adamantyl; 2-adamantyl, benzyl; and phenyl groups of the formula ##STR2## wherein R.sub.4 and R.sub.5 are the same or different and each is selected from the group consisting of hydrogen, halogen, alkyl having 1, 2, or 3 carbon atoms, alkoxy having 1, 2, or 3 carbon atoms, alkoxycarbonyl having 2-7 carbon atoms and alkylcarbonyl groups having 2-7 carbon atoms; or R.sub.4 and R.sub.5 together form a straight saturated alkylene chain having 3 or 4 carbon atoms and being bound to adjacent positions, i.e. 2,3- or 3,4- in the phenyl ring; and R.sub.3 is selected from the group consisting of hydrogen, alkyl groups containing 1-8 carbon atoms; cycloalkyl groups containing 3-8 carbon atoms; cycloalkyl-alkyl groups containing 4-8 carbon atoms; 1-adamantyl; 2-adamantyl; benzyl; and phenyl groups of the formula ##STR3## wherein R.sub.4 and R.sub.5 have the meaning given above; provided that at least one of the groups R.sub.1, R.sub.2 and R.sub.3 is alkyl, cycloalkyl, or cycloalkyl-alkyl as defined above, or 1-adamantyl, 2-adamantyl, or benzyl; and provided that when R.sub.3 is H, then one of R.sub.1 and R.sub.2 is alkyl, cycloalkyl, or cycloalkyl-alkyl as defined above, or 1-adamantyl, 2-adamantyl, or benzyl and the other of R.sub.1 and R.sub.2 is H; or a physiologically acceptable salt or an optical isomer thereof; novel compounds within formula I, methods for their preparation and their medicinal use.

  一种含有如下结构的化合物作为活性成分的制药制剂：其中R.sub.1和R.sub.2相同或不同，且每个都从氢、含有1-6个碳原子的烷基基团、含有3-6个碳原子的环烷基基团、含有4-6个碳原子的环烷基-烷基基团、1-金刚烷基、2-金刚烷基、苄基；以及如下结构的苯基团中的苯基团##STR2##其中R.sub.4和R.sub.5相同或不同，每个都从氢、卤素、含有1、2或3个碳原子的烷基、含有1、2或3个碳原子的烷氧基、含有2-7个碳原子的烷氧羰基和含有2-7个碳原子的烷基羰基基团中选取；或者R.sub.4和R.sub.5一起形成直链饱和的含有3或4个碳原子的烷基链，并与相邻位置即苯环中的2,3-或3,4-相连；R.sub.3从氢、含有1-8个碳原子的烷基基团、含有3-8个碳原子的环烷基基团、含有4-8个碳原子的环烷基-烷基基团、1-金刚烷基、2-金刚烷基、苄基；以及如下结构的苯基团中的苯基团##STR3##其中R.sub.4和R.sub.5具有上述给定的含义；前提是R.sub.1、R.sub.2和R.sub.3中至少有一个是如上所定义的烷基、环烷基或环烷基-烷基，或者1-金刚烷基、2-金刚烷基或苄基；并且当R.sub.3为H时，那么R.sub.1和R.sub.2中的一个是如上所定义的烷基、环烷基或环烷基-烷基，或者1-金刚烷基、2-金刚烷基或苄基，另一个是H；或其生理上可接受的盐或其光学异构体；公式I内的新化合物，其制备方法及其药用。
• Versatile Cp*Co(III)(LX) Catalyst System for Selective Intramolecular C–H Amidation Reactions
  作者：Jia Lee、Jeonghyo Lee、Hoimin Jung、Dongwook Kim、Juhyeon Park、Sukbok Chang

  DOI：10.1021/jacs.0c04448

  日期：2020.7.15

  Herein, we report the development of a tailored cobalt catalyst system of Cp*Co(III)(LX) toward intramolecular C-H nitrene insertion of azidoformates to afford cyclic carbamates. The cobalt complexes were easy to prepare and bench-stable, thus offering a convenient reaction protocol. The catalytic reactivity was significantly improved by the electronic tuning of the bidentate LX ligands, and the observed

  在此，我们报告了针对叠氮甲酸酯的分子内 CH 氮烯插入以提供环状氨基甲酸酯的 Cp*Co(III)(LX) 定制钴催化剂系统的开发。钴配合物易于制备且在实验室中稳定，因此提供了方便的反应方案。双齿LX配体的电子调谐显着提高了催化反应性，并且通过构象分析和过渡态的DFT计算使观察到的区域选择性合理化。新开发的钴催化剂体系的优异性能可广泛应用于温和条件下的 C(sp2)-H 和 C(sp3)-H 氨基甲酸化反应。
• Helicoselective Synthesis of Indolohelicenoids through Organocatalytic Central‐to‐Helical Chirality Conversion
  作者：Wen‐Lei Xu、Ru‐Xia Zhang、Hui Wang、Jie Chen、Ling Zhou

  DOI：10.1002/anie.202318021

  日期：2024.2.26

  A chiral-phosphoric-acid-catalyzed enantioselective cycloaddition-elimination cascade reaction was developed to access chiral azahelicenoid skeletons. This convergent approach offers an organocatalytic helicoselective route to obtain indolohelicenoids with high enantioselectivity. The prepared indolohelicenoids display positive photophysical and chiroptical properties, showcasing their potential utility

  开发了一种手性磷酸催化的对映选择性环加成-消除级联反应来获得手性氮杂螺烯骨架。这种收敛方法提供了一种有机催化螺旋选择性途径，以获得具有高对映选择性的吲哚螺烯类化合物。所制备的吲哚螺烯类化合物表现出正光物理和手性光学性质，展示了它们在有机光电材料中的潜在用途。
• Aliphatic derivatives of phosphonoformic acid, pharmaceutical compositions and methods for combating virus infections
  申请人：Astra Läkemedel Aktiebolag

  公开号：EP0003007A2

  公开（公告）日：1979-07-11

  1. A pharmaceutical preparation containing as active ingredient a compound of the formula wherein R, and R2 are the same or different, and each is selected from the group consisting of hydrogen, alkyl groups containing 1-6 carbon atoms; cycloalkyl groups containing 3-6 carbon atoms; cycloalkyl-alkyl groups containing 4-6 carbon atoms: 1-adamantyl; 2-adamantyl, benzyl; and phenyl groups of the formula wherein R. and R5 are the same or different, and each is selected from the group consisting of hydrogen, halogen, alkyl having 1, 2, or 3 carbon atoms, alkoxy having 1, 2, or 3 carbon atoms, alkoxycarbonyl having 2-7 carbon atoms and alkylcarbonyl groups having 2-7 carbon atoms; or R. and R5 together form a straight saturated alkylene chain having 3 or 4 carbon atoms and being bound to adjacent positions, i.e. 2,3- or 3,4- in the phenyl ring; and R3 is selected from the group consisting of hydrogen, alkyl groups containing 1-8 carbon atoms; cycloalkyl groups containing 3-8 carbon atoms; cycloalkyl-alkyl groups containing 4-8 carbon atoms; 1-adamantyl; 2- adamantyl; benzyl; and phenyl groups of the formula wherein R4 and Rs have the meaning given above; provided that at least one of the groups R,, R2 and R3 is alkyl, cycloalkyl, or cycloalkyl-alkyl as defined above, or 1-adamantyl, 2-adamantyl, or benzyl; and provided that when R3 is H, then one of R, and R2 is alkyl, cycloalkyl, or cycloalkyl-alkyl as defined above, or 1-adamantyl, 2-adamantyl, or benzyl and the other of R, and R2 is H; or a physiologically acceptable salt or an optical isomer thereof; novel compounds within formula I, methods for their preparation and their medicinal use.

  1.一种药物制剂，其活性成分为如下式中的化合物 其中 R 和 R2 相同或不同，且各自选自由下列组成的组氢、含 1-6 个碳原子的烷基、含 3-6 个碳原子的环烷基、含 4-6 个碳原子的环烷基-烷基：1-金刚烷基；2-金刚烷基；苄基；以及式中的苯基。 其中 R.和 R5 相同或不同，且各自选自由氢、卤素、具有 1、2 或 3 个碳原子的烷基、具有 1、2 或 3 个碳原子的烷氧基、具有 2-7 个碳原子的烷氧羰基和具有 2-7 个碳原子的烷基羰基组成的组；或 R.和 R5 共同形成具有 3 或 4 个碳原子的直链饱和亚烷基，并结合到苯基环的相邻位置，即 2,3- 或 3,4- 位； R3 选自氢、含 1-8 个碳原子的烷基、含 3-8 个碳原子的环烷基、含 4-8 个碳原子的环烷基-烷基、1-金刚烷基、2-金刚烷基、苄基和式中的苯基所组成的组。 其中 R4 和 Rs 具有上述含义；条件是基团 R、R2 和 R3 中至少有一个是如上定义的烷基、环烷基或环烷基-烷基，或 1-金刚烷基、2-金刚烷基或苄基；且当 R3 为 H 时，则 R 和 R2 中的一个为如上定义的烷基、环烷基或环烷基-烷基，或 1-金刚烷基、2-金刚烷基或苄基，而 R 和 R2 中的另一个为 H；或其生理上可接受的盐或光学异构体；式 I 内的新型化合物、其制备方法及其药用用途。
• FLUORINATED CYCLOPROPYLAMINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USERS THEREOF
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：EP3431471A1

  公开（公告）日：2019-01-23

  Provided are a compound represented by formula I, a raceme thereof, an R-isomer thereof, an S-isomer thereof, a pharmaceutical salt thereof, and a mixture thereof, a preparation method therefor, a pharmaceutical composition comprising the compound, and uses thereof serving as an lysine specific demethylase 1 (LSD1) inhibitor. Provided are uses of the fluorinated cyclopropylamine compound represented by formula I in the treatment of cancers.

  提供一种由式 I 代表的化合物、其外消旋体、其 R-异构体、其 S-异构体、其药用盐和其混合物、其制备方法、包含该化合物的药物组合物以及其作为赖氨酸特异性去甲基化酶 1（LSD1）抑制剂的用途。提供了式 I 所代表的氟化环丙胺化合物在治疗癌症中的用途。